Arndt Vogel Highlighted Study on Zanidatamab plus Chemotherapy as First-line Treatment for HER2-positive GC/GEJ Cancer
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School, shared a post on X:
“Zanidatamab plus chemotherapy as first-line treatment for HER2-positive GC/GEJ cancer, published in the Lancet Oncology.
Single-arm, phase 2
– ORR 76·2%
– mPFS 12·5 mo
– mOS 36·5 mo
Looks promising, now combo with ICI, phase 3 awaited.”
Title: Zanidatamab plus chemotherapy as first-line treatment for patients with HER2-positive advanced gastro-oesophageal adenocarcinoma: primary results of a multicentre, single-arm, phase 2 study
Journal: Lancet Oncology
Authors: Elena Elimova, Jaffer Ajani, Howard Burris, Crystal S. Denlinger, Syma Iqbal, Yoon-Koo Kang, Jwa Hoon Kim, Keun-Wook Lee, Bruce Lin, Rutika Mehta, Do-Youn Oh, Sun Young Rha, Young Mi Seol, Lin Yang, Mark A. Ozog, Phillip M. Garfin, Geoffrey Ku
More posts featuring Arndt Vogel on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023